Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress

Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemigatinib, whose approval has marked a new era in thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadaleta-Caldarola, Gennaro, Rizzo, Alessandro, Dadduzio, Vincenzo, Lombardi, Lucia, Gadaleta-Caldarola, Arianna, Infusino, Stefania, Cusmai, Antonio, Citrigno, Claudia, Palmiotti, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600707/
https://www.ncbi.nlm.nih.gov/pubmed/36290903
http://dx.doi.org/10.3390/curroncol29100626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600707/
https://www.ncbi.nlm.nih.gov/pubmed/36290903
http://dx.doi.org/10.3390/curroncol29100626

Ejemplares similares